SCHEMBL7874375

SCHEMBL7874375

CONC(=O)c1ccc(C(=O)c2cc3c(cc2C)C(C)(C)CCC3(C)C)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 19/20 0.56
RXRB P28702 10/20 0.51
RXRG P48443 10/20 0.51
RARB P10826 6/20 0.51
RARG P13631 6/20 0.51
RARA P10276 5/20 0.51
PPARG P37231 2/20 0.47
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46
CYP26A1 O43174 2/20 0.44
CYP26B1 Q9NR63 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6902498 0.87 RXRA (0.60) RXRARXRBRXRGRARBRARG
SCHEMBL7870773 0.87 RXRA (0.61) RXRARXRBRXRGRARBRARG
SCHEMBL8330713 0.85 RXRA (0.49) RXRARXRBRXRGRARBRARG
SCHEMBL1072538 0.85 RXRA (0.67) RXRARXRBRXRGRARBRARG
SCHEMBL6890738 0.83 RXRA (0.78) RXRARXRBRXRGRARBRARG
SCHEMBL12426169 0.83 RXRA (0.60) RXRARXRBRXRGRARBRARG
SCHEMBL5537864 0.81 RXRA (0.59) RXRARXRBRXRGRARBRARG
SCHEMBL14212722 0.80 RXRA (0.52) RXRARXRBRXRGRARBRARG
SCHEMBL6890125 0.80 RXRA (0.72) RXRARXRBRXRGRARBRARG
SCHEMBL8330521 0.78 RXRA (0.51) RXRARXRBRXRGRARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6320074-B1 IN VIVO MODULATION OF LIPID METABOLISM, SKIN-RELATED PROCESSES, AUTOIMMUNE DISEASES, FATTY ACID METABOLISM, MALIGNANT CELL DEVELOPMENT, PREMALIGNANT LESIONS, OR PROGRAMMED CELL DEATH LIGAND PHARMACEUTICALS INCORPORATED 2001-11-20 US claimed
EP-0678086-B1 COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS LIGAND PHARM INC (US) 1999-12-08 EP claimed
EP-0678086-A1 COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS LIGAND PHARMACEUTICALS, INC. (US) 1995-10-25 EP claimed
WO-1994015902-A1 COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS LIGAND PHARMACEUTICALS INC. (US) 1994-07-21 WO claimed